These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 36623239

  • 21. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J.
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
    Shi Z, Lu L, Resurreccion WK, Yang W, Wei J, Wang Q, Engelmann V, Zheng SL, Cooney KA, Isaacs WB, Helfand BT, Lu J, Xu J.
    Prostate; 2022 Jan; 82(1):107-119. PubMed ID: 34674288
    [Abstract] [Full Text] [Related]

  • 24. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB, Kirichek AA, Filippova MG, Savinkova AV, Khalmurzaev OA, Lyubchenko LN.
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [Abstract] [Full Text] [Related]

  • 25. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.
    Loeb S, Giri VN.
    Eur Urol Oncol; 2021 Feb; 4(1):1-9. PubMed ID: 33390340
    [Abstract] [Full Text] [Related]

  • 26. Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer.
    Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, Small EJ, Dhawan M.
    JCO Oncol Pract; 2023 May; 19(5):e773-e783. PubMed ID: 36649492
    [Abstract] [Full Text] [Related]

  • 27. Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.
    Gheybi K, Jiang J, Mutambirwa SBA, Soh PXY, Kote-Jarai Z, Jaratlerdsiri W, Eeles RA, Bornman MSR, Hayes VM.
    J Natl Compr Canc Netw; 2023 Mar; 21(3):289-296.e3. PubMed ID: 36898365
    [Abstract] [Full Text] [Related]

  • 28. Germline DNA-Repair Genes and HOXB13 Mutations in Korean Men with Metastatic Prostate Cancer: Data from a Large Korean Cohort.
    Song SH, Kim HM, Jung YJ, Kook HR, Jeon S, Bhak J, Kim JH, Lee H, Oh JJ, Lee S, Hong SK, Byun SS.
    World J Mens Health; 2023 Oct; 41(4):960-968. PubMed ID: 37118955
    [Abstract] [Full Text] [Related]

  • 29. Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
    Wei J, Yang W, Shi Z, Lu L, Wang Q, Resurreccion WK, Engelmann V, Zheng SL, Hulick PJ, Cooney KA, Isaacs WB, Helfand BT, Lu J, Xu J.
    Prostate; 2021 Sep; 81(13):1002-1008. PubMed ID: 34254341
    [Abstract] [Full Text] [Related]

  • 30. Germline Testing in Prostate Cancer: When and Who to Test.
    Sokolova A, Cheng H.
    Oncology (Williston Park); 2021 Oct 20; 35(10):645-653. PubMed ID: 34669358
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prostate Cancer Screening in a New Era of Genetics.
    Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS.
    Clin Genitourin Cancer; 2017 Dec 20; 15(6):625-628. PubMed ID: 28697982
    [Abstract] [Full Text] [Related]

  • 33. Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO.
    Hoffman TL, Kershberg H, Goff J, Holmquist KJ, Haque R, Alvarado M.
    Fam Cancer; 2023 Apr 20; 22(2):225-235. PubMed ID: 36261688
    [Abstract] [Full Text] [Related]

  • 34. Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness.
    Pritchard CC.
    Can J Urol; 2019 Oct 20; 26(5 Suppl 2):24-26. PubMed ID: 31629422
    [Abstract] [Full Text] [Related]

  • 35. Germline and Somatic Mutations in Prostate Cancer for the Clinician.
    Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS.
    J Natl Compr Canc Netw; 2019 May 01; 17(5):515-521. PubMed ID: 31085765
    [Abstract] [Full Text] [Related]

  • 36. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.
    Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O'Leary E, Esplin ED, Nussbaum RL, Sartor O.
    JAMA Oncol; 2019 Apr 01; 5(4):523-528. PubMed ID: 30730552
    [Abstract] [Full Text] [Related]

  • 37. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.
    Darst BF, Saunders E, Dadaev T, Sheng X, Wan P, Pooler L, Xia LY, Chanock S, Berndt SI, Wang Y, Patel AV, Albanes D, Weinstein SJ, Gnanapragasam V, Huff C, Couch FJ, Wolk A, Giles GG, Nguyen-Dumont T, Milne RL, Pomerantz MM, Schmidt JA, Travis RC, Key TJ, Stopsack KH, Mucci LA, Catalona WJ, Marosy B, Hetrick KN, Doheny KF, MacInnis RJ, Southey MC, Eeles RA, Wiklund F, Conti DV, Kote-Jarai Z, Haiman CA.
    JAMA Oncol; 2023 Nov 01; 9(11):1514-1524. PubMed ID: 37733366
    [Abstract] [Full Text] [Related]

  • 38. Outcomes of a universal germline screening program in a community urology practice.
    Mendhiratta N, Hauver H, Hatton W, Ostrusky A, Sathe DS, Gurram S, Rice P, Chalfin H.
    Clin Genet; 2024 Sep 01; 106(3):277-283. PubMed ID: 38711401
    [Abstract] [Full Text] [Related]

  • 39. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
    Lee DJ, Hausler R, Le AN, Kelly G, Powers J, Ding J, Feld E, Desai H, Morrison C, Doucette A, Gabriel P, Genetics Center R, Judy RL, Weaver J, Kember R, Damrauer SM, Rader DJ, Domchek SM, Narayan V, Schwartz LE, Maxwell KN.
    Eur Urol; 2022 Jun 01; 81(6):559-567. PubMed ID: 34711450
    [Abstract] [Full Text] [Related]

  • 40. Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance.
    Brady L, Newcomb LF, Zhu K, Zheng Y, Boyer H, Sarkar N, McKenney JK, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss MA, Martin F, Morgan TM, Thompson IM, Wagner AA, Pritchard CC, Lin DW, Nelson PS.
    Cancer Med; 2022 Nov 01; 11(22):4332-4340. PubMed ID: 35467778
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.